What is Adam O’Dell x.AI Stock Pick?

Wondering what x.AI is as pitched by Adam O’Dell?

Money and Market, an independent financial publishing firm, has been promoting a new pitch by Adam O’Dell called “x.AI.”

It concerns a new development in artificial intelligence that Adam has been telling investors to get involved with because it could result in an $80 trillion windfall in the next ten years.

Let’s take a look at what Adam was proposing in his presentation and learn more about his outlook on Artificial Intelligence.

No.1 recommendation….

Want to see my no.1 recommendation for making money online?

This made us 6-figures in the last 3 months:

Go here to see my no.1 recommendation for making money online

What is Adam O’Dell x.AI?

Adam O’Dell’s “X.AI” is a pitch about a new investment opportunity involving Artificial Intelligence.

Artificial Intelligence and machine learning are already pervasive in our modern lives but according to Adam, they could have an even farther reach and make people very rich if they invest in the right companies.

Adam O Dell xAI So far, it is used for a wide range of applications, including digital assistants like Alexa and Siri and search engines.

And now Adam believes that big tech companies and government agencies are working on advancing AI so that it will have a wider range of uses for their clients and the country.

He says that Congress even recently passed a bill with bipartisan support to further boost AI development.

As this happens, he claims that there is one tiny company that is in an industry called “x.AI.” He talks about it as being a great company to invest in because an investment in it will earn you returns for months and years to come.

When you watch the presentation, although he never explicitly says it, you can tell that he is talking about the healthcare/biotech industry when he refers to “x.AI.”

This is a common tactic used by newsletter gurus to take a relatively straightforward idea and add a level of obscurity to make it interesting.

In this case, Adam is telling us to focus on a tiny company in the biotech industry that uses AI.

Again, over the past few weeks, many analysts have come out talking about biotech companies that are using artificial intelligence to develop new drugs. A good example of this is Jeff Brown’s OMNIA Technology presentation.

The drug development process is usually long and costly. Some within the industry estimate that it takes ten years and costs $2.6 billion to bring a drug to market.

Now, Adam is talking about how AI and machine learning are being used to streamline the drug discovery process to minimize the cost and trim the timeline.

Artificial Intelligence in the drug discovery process is not an alien idea.

AI is used at various stages of development:

In the first step of discovery, it is used to analyze existing literature to examine how potential new drugs will interact with the targets.

Then in preclinical trials when the drug is tested on animal models, AI allows researchers to run the trials faster and more effectively.

When the FDA gives the go-ahead, the next step is clinical trials. It is a four-stage process considered the most time- and resource-consuming.

AI helps with the monitoring of the trials to enable researchers to generate a lot more useful data faster and personalize the trial experience. The AI identifies many compounds in a short period and at a quarter the cost of the traditional method.

In his pitch, Adam O’Dell has focused on one company that is working on AI-based cures for Cancer.

It is developing solutions that have a high success rate in cancer diagnosis. It even has a way to predict more stable and effective outcomes for cancer patients by using data generated by an AI-based system.

All details about this company are in a special report called NGS Fortunes: The #1 x.AI Company Working to Eradicate Cancer.

If you want to invest in the company, you have to read this report, and to do that, you have to subscribe to Adam’s newsletter, Green Zone Fortunes.

Recommended: Go here to see my no.1 recommendation for making money

Who is Adam O’Dell?

Adam O’Dell is an investment analyst who publishes his work via Money & Markets, an independent research firm that publishes financial newsletters and articles targeting retail investors.

He is the editor of Home Run Profits and Green Zone Fortunes.

He is a Chartered Market Technician (CMT) qualification and also has an MBA.

Adam is a former hedge fund manager and he started writing about the capital markets and publishing his thoughts on investments in 2012.

He points out that once he began his publishing career, he could have earned bigger returns with his recommendations than some of the most well-known and seasoned investors on Wall Street. He also claims to have beaten the S&P 500 by more than five times.

Adam O’Dell writes about multiple asset classes, including stocks, bonds, and gold. It has been his goal throughout to find good investment opportunities in any market.

Recommended: Go here to see my no.1 recommendation for making money

Green Zone Fortunes Review

Adam O’Dell’s Green Zone Fortunes is a multifaceted investment research service that focuses on new investment opportunities in a wide range of market niches.

When you sign up for Green Zone Fortunes, you get:

  • A 1-Year Membership to Green Zone Fortunes. Every month, Adam O’Dell sends you a newsletter revealing the company he regards as the No. 1 stock in the markets. The email includes detailed research and analysis.
  • You get 24/7 access to the members-only website where you can find his live model portfolio and past research reports.
  • Access to the Green Zone Fortunes “Weekly Hotlist”. Every week, Adam analyzes 8,000 U.S. stocks using the Green Zone Rating system. He then highlights the top 10 best-performing stocks and the top 10 worst-performing stocks every Wednesday.

In addition to these perks, you receive special reports with bonus investment opportunities. Examples are:

  • NGS Fortunes: The #1 x.AI Company Working to Eradicate Cancer
  • Precision Profits: The Tiny Company Creating the Blueprint for Personalized Drug Discovery
  • Tomorrow’s Edge: The x.AI Company Treating HIV and Infectious Disease

Recommended: Go here to see my no.1 recommendation for making money

Green Zone Fortunes Pricing

The first year of your subscription is $47.

Your membership auto-renews for $79 and it becomes the annual fee every year.

If you don’t want to pay, you can always cancel your subscription by contacting customer support.

The Green Zone Fortunes Refund Policy

Green Zone Fortunes has a 365-day, 100% money-back guarantee.

Closing Remarks on Adam O’Dell x.AI

Adam O’Dell’s “xAI” is all about investing in companies in the biotech industry that are using AI in drug discovery.

Many investment analysts have been talking about these companies in the past few weeks and it looks like Adam is joining in with his take.

There is a feeling among investment gurus that investing in a company that uses AI to streamline the drug discovery process will earn you decent returns.

Before you go…

Want to see my no.1 recommendation for making money online?

This made us 6-figures in the last 3 months:

Go here to see my no.1 recommendation for making money online